Universal Vision Biotechnology Co., Ltd. (TPEX:3218)
143.00
+0.50 (0.35%)
Oct 31, 2025, 2:31 PM CST
TPEX:3218 Revenue
Universal Vision Biotechnology had revenue of 1.02B TWD in the quarter ending June 30, 2025, a decrease of -1.59%. This brings the company's revenue in the last twelve months to 4.26B, up 2.37% year-over-year. In the year 2024, Universal Vision Biotechnology had annual revenue of 4.23B with 3.58% growth.
Revenue (ttm)
4.26B
Revenue Growth
+2.37%
P/S Ratio
2.84
Revenue / Employee
10.63M
Employees
401
Market Cap
12.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.23B | 146.05M | 3.58% |
| Dec 31, 2023 | 4.08B | 588.20M | 16.83% |
| Dec 31, 2022 | 3.49B | 862.26M | 32.76% |
| Dec 31, 2021 | 2.63B | 578.66M | 28.18% |
| Dec 31, 2020 | 2.05B | 634.16M | 44.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| PharmaEssentia | 12.63B |
| Pegavision | 6.90B |
| Center Laboratories | 1.60B |
| Oneness Biotech | 112.57M |
| Polaris Group | 64.02M |
| Caliway Biopharmaceuticals | 44.83M |